ICON Wins Pharma Contract Services Company of the Year at the Pharma Industry Awards 2018
2018年10月25日 - 8:00PM
ビジネスワイヤ(英語)
The Pharma Industry Awards recognise and
celebrate innovative individuals and companies that demonstrate
excellence in the Irish Pharma sector
ICON plc, (NASDAQ: ICLR) a global provider of drug
development services to the pharmaceutical, biotechnology and
medical device industries, today announced that it has been awarded
Pharma Contract Services Company of the Year for the second time.
The award was presented at the annual Pharma Industry Awards which
took place in Dublin on 23 October 2018.
The Pharma Industry Awards is the premier awards ceremony for
recognising and celebrating the most original and innovative
individuals and companies that demonstrate excellence in the Irish
Pharma sector. The Pharma Contract Services Company of the Year
award was judged under the following criteria:
- Outstanding achievement
- Business growth
- Operational excellence
- Innovativeness
- Societal Impact
- Professional standing and
accreditation
Commenting on the award, ICON’s Chief Executive Officer, Dr.
Steve Cutler, said “We are thrilled to be honoured as the
industry’s best contract services company for 2018. Over the past
year we have continued to grow as a global leader in clinical
research, helping our clients develop their products through
operational excellence and quality innovation and solutions. We are
delighted that our employees’ hard work and dedication are being
recognised and that this award adds to the number of high-profile
industry awards received over the past year, recognising ICON as
one of the world’s leading Contract Research Organisations.”
About ICON plcICON plc is a global provider of outsourced
drug development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and
public health organisations. The company specializes in the
strategic development, management and analysis of programs that
support clinical development from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 93 locations in 37 countries and has
approximately 13,675 employees.
Further information is available at https://www.iconplc.com/news-events/awards/
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181025005366/en/
ICON Media ContactLucinda Sandon-AllumWeber Shandwick+44
(0)20 7067 0548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024